论文部分内容阅读
目的应用液体芯片技术检测癌胚抗原(CEA)、19片段角蛋白(CYFRA21-1)和神经元特异性烯醇化酶(NSE),探讨液体芯片技术在肿瘤标志物检测中的应用价值以及在肺癌诊断中血清CEA、CYFRA21-1和NSE含量的变化及联合检测的意义。方法应用液体芯片技术测定81例肺癌、58例肺良性病变的患者及80例健康者血清CEA、CYFRA21-1和NSE浓度,测定结果与微粒子酶免分析法(MEIA)、酶联免疫吸附实验及电化学发光检测结果比较。结果液体芯片试剂盒与比对试剂盒检测结果无显著差异,联合检测三种肿瘤标志物对于肺癌诊断的敏感性高于单一或两种肿瘤标志物。结论血清CEA、CYFRA21-1和NSE的联合检测对肺癌诊断有较高的临床参考价值;液体芯片技术可同时高通量检测多指标,可用于临床检测。
Objective To detect the value of CEA, CYFRA21-1 and NSE by liquid microarray in order to explore the value of liquid microarray in the detection of tumor markers, Changes of Serum CEA, CYFRA21-1 and NSE in Diagnosis and Significance of Combined Detection. Methods Serum levels of CEA, CYFRA21-1 and NSE in 81 patients with lung cancer, 58 patients with benign lung disease and 80 healthy controls were determined by liquid microarray. The results were compared with ELISA, MEIA, Electrochemiluminescence detection results comparison. Results There was no significant difference between the liquid chip kit and the matched kit. The combined detection of the three tumor markers was more sensitive to the diagnosis of lung cancer than single or two tumor markers. Conclusion The combined detection of serum CEA, CYFRA21-1 and NSE has high clinical value in the diagnosis of lung cancer. Liquid chip technology can simultaneously detect high-throughput multi-index and can be used for clinical detection.